Possibilities of using coenzyme Q10 for the treatment of diseases associated with mitochondrial dysfunction and chronic inflammation

O. A. Gromova, I. Yu. Torshin, A. N. Gromov
{"title":"Possibilities of using coenzyme Q10 for the treatment of diseases associated with mitochondrial dysfunction and chronic inflammation","authors":"O. A. Gromova, I. Yu. Torshin, A. N. Gromov","doi":"10.17749/2070-4909/farmakoekonomika.2023.187","DOIUrl":null,"url":null,"abstract":"Background. The enzymatic cofactor coenzyme Q10 (CoQ10) is involved in the synthesis of adenosine triphosphate in mitochondria. The CoQ10 biosynthesis declines when using statin drugs. Objective : systematization of the impact of coenzyme Q10 on chronic, sluggish systemic inflammation leading to the development of atherosclerosis, liver and pancreas pathologies, and neurodegeneration. Material and methods. Systematic computer analysis of 16,788 publications on CoQ10 found by the query “coenzyme Q10 OR ubiquinone” in PubMed/MEDLINE database of biomedical publications was carried out. Current methods of topological and metric data analysis developed at the scientific school of Academician of the Russian Academy of Sciences Yu.I. Zhuravlev were used. Results. CoQ10 is involved in the regulation of inflammation and exhibits lipid-lowering, hepatoprotective, nephroprotective, anti-asthenic, cardioprotective, and neuroprotective effects. CoQ10 favorably affects carbohydrate metabolism and a wide range of neurological diseases. Conclusion. CoQ10 supplementation improves glycemic control in insulin resistance, kidney function, and is useful in the treatment of migraine and neurodegenerative pathologies (Parkinson’s disease, etc.).","PeriodicalId":36464,"journal":{"name":"Farmakoekonomika","volume":" 13","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmakoekonomika","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.187","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background. The enzymatic cofactor coenzyme Q10 (CoQ10) is involved in the synthesis of adenosine triphosphate in mitochondria. The CoQ10 biosynthesis declines when using statin drugs. Objective : systematization of the impact of coenzyme Q10 on chronic, sluggish systemic inflammation leading to the development of atherosclerosis, liver and pancreas pathologies, and neurodegeneration. Material and methods. Systematic computer analysis of 16,788 publications on CoQ10 found by the query “coenzyme Q10 OR ubiquinone” in PubMed/MEDLINE database of biomedical publications was carried out. Current methods of topological and metric data analysis developed at the scientific school of Academician of the Russian Academy of Sciences Yu.I. Zhuravlev were used. Results. CoQ10 is involved in the regulation of inflammation and exhibits lipid-lowering, hepatoprotective, nephroprotective, anti-asthenic, cardioprotective, and neuroprotective effects. CoQ10 favorably affects carbohydrate metabolism and a wide range of neurological diseases. Conclusion. CoQ10 supplementation improves glycemic control in insulin resistance, kidney function, and is useful in the treatment of migraine and neurodegenerative pathologies (Parkinson’s disease, etc.).
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用辅酶Q10治疗与线粒体功能障碍和慢性炎症相关疾病的可能性
背景。辅酶辅酶Q10 (CoQ10)参与线粒体中三磷酸腺苷的合成。使用他汀类药物时,辅酶q10的生物合成下降。目的:系统化研究辅酶Q10对导致动脉粥样硬化、肝脏和胰腺病变以及神经变性的慢性、迟缓的全身性炎症的影响。材料和方法。对在PubMed/MEDLINE生物医学出版物数据库中通过查询“coenzyme Q10 OR ubiquinone”查询到的辅酶Q10相关文献16,788篇进行了系统的计算机分析。目前的拓扑和度量数据分析方法是由俄罗斯科学院院士yui的科学学院开发的。朱拉夫列夫被使用了。结果。辅酶q10参与炎症调节,并表现出降脂、保肝、保肾、抗衰弱、保心脏和保神经的作用。辅酶q10积极影响碳水化合物代谢和广泛的神经系统疾病。结论。补充辅酶q10可改善胰岛素抵抗、肾功能的血糖控制,并可用于治疗偏头痛和神经退行性疾病(帕金森病等)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Farmakoekonomika
Farmakoekonomika Medicine-Health Policy
CiteScore
1.70
自引率
0.00%
发文量
43
审稿时长
8 weeks
期刊最新文献
Updated pharmacoeconomic analysis of atesolizumab efficiency compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study Retrospective pharmacoeconomic study of antibiotic therapy in community-acquired pneumonia The role of ferritin in liver disease assessment An open-label, controlled trial of the clinical effects of Laennec® in patients with nonalcoholic steatohepatitis or cirrhosis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1